Is Gian Lifecare overvalued or undervalued?

As of 1 July 2025, the valuation grade for Gian Lifecare has moved from very attractive to risky. The company appears to be overvalued based on its current financial metrics. Key ratios include a PE ratio of 3.96, an EV to EBITDA of 2.19, and a PEG ratio of 0.02, which are significantly lower than those of its peers. For instance, Max Healthcare has a PE ratio of 109.83 and Apollo Hospitals has a PE of 74.52, indicating that Gian Lifecare's valuation does not align with industry standards.
In comparison to its peers, Gian Lifecare's financial performance is concerning, particularly given its low valuation ratios. The company has underperformed the Sensex, with a year-to-date stock return of -20.8% compared to the Sensex's gain of 7.11%. Overall, Gian Lifecare is considered overvalued in the current market environment.